Amedica (NASDAQ: AMDA) and Stryker (NYSE:SYK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Risk and Volatility

Amedica has a beta of -2.08, meaning that its share price is 308% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amedica and Stryker, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedica 0 2 0 0 2.00
Stryker 2 7 12 0 2.48

Amedica presently has a consensus price target of $60.00, suggesting a potential upside of 1,933.90%. Stryker has a consensus price target of $153.58, suggesting a potential downside of 0.44%. Given Amedica’s higher possible upside, equities research analysts clearly believe Amedica is more favorable than Stryker.

Dividends

Stryker pays an annual dividend of $1.70 per share and has a dividend yield of 1.1%. Amedica does not pay a dividend. Stryker pays out 36.3% of its earnings in the form of a dividend. Stryker has increased its dividend for 6 consecutive years.

Valuation and Earnings

This table compares Amedica and Stryker’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amedica $15.23 million 0.58 -$16.59 million N/A N/A
Stryker $11.33 billion 5.10 $1.65 billion $4.68 32.96

Stryker has higher revenue and earnings than Amedica.

Institutional and Insider Ownership

63.6% of Amedica shares are held by institutional investors. Comparatively, 75.0% of Stryker shares are held by institutional investors. 0.1% of Amedica shares are held by company insiders. Comparatively, 7.4% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Amedica and Stryker’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amedica -87.49% -77.71% -45.50%
Stryker 14.67% 24.11% 11.44%

Summary

Stryker beats Amedica on 13 of the 15 factors compared between the two stocks.

Amedica Company Profile

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.